Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cervical Cancer, Cervical Cancer, Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/19/2018 |
| Start Date: | February 2012 |
| End Date: | January 1, 2019 |
The purpose of this study is to measure the levels of serum proteins and other biomarkers in
cervical cancer patients. We believe that some of these markers may be useful in selecting
patients for specific types of cancer therapies. These markers may also help to predict
response to therapy, relapse after therapy, and survival after therapy.
cervical cancer patients. We believe that some of these markers may be useful in selecting
patients for specific types of cancer therapies. These markers may also help to predict
response to therapy, relapse after therapy, and survival after therapy.
SPECIFIC STUDY AIMS
Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a
gene expression signature that predicts for lymph node metastases in this disease.
Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of
cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma
samples.
Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples
of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and
determine its ability to predict for nodal metastases.
Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between
cervical cancer patients with and without lymph node metastasis.
Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a
gene expression signature that predicts for lymph node metastases in this disease.
Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of
cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma
samples.
Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples
of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and
determine its ability to predict for nodal metastases.
Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between
cervical cancer patients with and without lymph node metastasis.
Inclusion Criteria:
- Patients must have a known or suspected cervical cancer.
- Age >=18 years.
- Patients must have no other active cancer at the time of diagnosis.
- Patients must have no history of a hysterectomy.
- Patients must be able to give informed consent.
- Patients must be willing to undergo a biopsy of the cervical tumor to provide tissue
for the study.
- Patients must have completed a standard-of-care FDG-PET/CT prior to initiation of
therapy, for assessment of lymph nodes.
Exclusion Criteria:
- Pregnant women
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
